To investigate the anti-cancer effect of NRF2 inhibitors combined with GPX4 inhibitors, we chose three NRF2 inhibitors (trigonelline (TRI), Clobetasol propionate (CP), and ML385) and two GPX4 inhibitors (RSL3 and ML210). Here, GPX4 is linked to cancer.